ライフサイエンスコーパス: KLH

1 KLH added to DC immunizations markedly enhances tumor-sp

2 KLH conjugate 2 has been subsequently submitted to precl

3 KLH had a different safety profile and was inferior to M

4 KLH tended to be more effective than MM in preventing pr

5 antibodies generated in response to the KH-1-KLH construct recognized not only KH-1 antigen but also

6 yl hapten-keyhole limpet hemocyanin (DNP(23)-KLH).

7 Human T cells from DNP(23)-KLH-immunized mice showed strong proliferation in respon

8 Vaccination with 6OXY(Gly)(4)-KLH increased drug binding in serum, reduced drug distri

9 The 6OXY(Gly)(4)-KLH vaccine may be used for treatment of prescription op

10 dents as a candidate immunogen (6OXY(Gly)(4)-KLH) for the treatment of oxycodone abuse.

11 codone effects but less so than 6OXY(Gly)(4)-KLH.

12 jugated to keyhole limpet hemocyanin (NP(5)- KLH) or infected with HSV-1, and the Ab response was eva

13 ein to restore the humoral response to NP(5)-KLH in C4-deficient animals when administered along with

14 However, boosting with 4P-8-KLH after immunizing with LPS prolonged the LPS-reactive

15 In addition, 4P-8-KLH was able to elicit anti-LPS Abs in mice, but the imm

16 hemocyanin (KLH) mixed with HKL generated a KLH-specific primary response characterized by productio

17 thioether conjugation to maleimide activated KLH (mKLH).

18 ose injections of CORT on days 5 and 7 after KLH had anti-KLH IgG levels equal to those of sham-opera

19 at the small rise in GC found 4-7 days after KLH facilitates IgG2a isotype switching.

20 nd fatigue occurred significantly more after KLH treatment.

21 y proliferated in response to the protein Ag KLH presented by host MHC following in vivo immunization

22 control birds, which were immunized against KLH.

23 All KLH primed animals not receiving the exogenous antigen a

24 diabetic rats immunized with adjuvant alone, KLH-immunized diabetic rats had decreased levels of glyc

25 In univariate Cox regression analyses, KLH tended to prevent progression more effectively than

26 te and multivariate Cox regression analysis, KLH was less effective than MM regarding RFS (all P < .0

27 intradermal injections of HPV E7 antigen and KLH were detected for all patients after vaccination.

28 ransferred to cultures of CD4(+) T cells and KLH-pulsed spleen cells from GM-CSF -/- mice.

29 MoDC contained significantly more HLA-DR and KLH than those purified from control MoDC, and KLH was c

30 nd cellular immunity against HPV16/18 E7 and KLH were monitored.

31 H than those purified from control MoDC, and KLH was concentrated specifically in exosomes that were

32 Syntheses of both nonconjugate and KLH-conjugated vaccines constructs have been accomplishe

33 sterolemia responded to a one-time OxLDL and KLH challenge with greater OxLDL-specific IgM responses,

34 nus toxoid, pneumococcal polysaccharide, and KLH vaccines as well as a Candida albicans skin test wer

35 rmine if the foreign helper proteins (TT and KLH) were essential for CD8(+) T-cell responses to the v

36 Antitetanus, antipneumococcal, and anti-KLH serum IgG levels were measured prior to and 4 weeks

37 vaccine (47% of patients had detectable anti-KLH IgG, compared with 93% of patients treated with MTX

38 uced T-cell proliferation and serum for anti-KLH antibody was obtained at baseline and after feeding,

39 s of CORT on days 5 and 7 after KLH had anti-KLH IgG levels equal to those of sham-operated controls.

40 nization in the control group; however, anti-KLH antibody was seen after oral administration in both

41 ocyanin (KLH) resulted in a decrease in anti-KLH IgG accompanied by increases of anti-KLH IgA and IgE

42 limpet hemocyanin (KLH) Ab, increasing anti-KLH IgG, IgG2a, and IgE, whereas B7.2-Fc did not affect

43 nti-KLH IgG accompanied by increases of anti-KLH IgA and IgE.

44 ts with no CORT replacement had reduced anti-KLH IgM and IgG responses compared with sham-operated co

45 CORT replacement had partially restored anti-KLH IgM, but still had suppressed anti-KLH IgG.

46 studies show that patients make strong anti-KLH responses despite recent high-dose therapy and that

47 anti-KLH IgM, but still had suppressed anti-KLH IgG.

48 gG2a and splenic IFN-gamma, but not the anti-KLH IgG1, response.

49 GC receptor blockade reduced the anti-KLH IgG2a and splenic IFN-gamma, but not the anti-KLH Ig

50 ) receptor antagonists also reduced the anti-KLH IgM and IgG responses.

51 ed peptides from rat serum reacted with anti-KLH antibodies at a faster rate than normal IgG and sele

52 er in vitro stimulation with carrier antigen KLH.

53 uced an immune response to control antigens (KLH, Flu-MP) in 16 of 18 patients.

54 ma, we demonstrate that DCs pulsed with both KLH and tumor lysate mediate enhanced immune priming and

55 reduced, as were surface HLA-DR and DR-bound KLH-derived peptides.

56 eukin 2 augments the enhancement afforded by KLH, as measured by cure rates and overall survival, in

57 ce immunized with P315-KLH were inhibited by KLH treated with glutaraldehyde (KLH-g), but not by P315

58 infer that the presence of IL-4 secreted by KLH-specific memory Th2 cells in the lymphoid system mic

59 Patients received Tn(c)-KLH vaccine containing either 3, 7, or 15 microg of Tn(c

60 When compared with the corresponding KLH-epitope conjugates in C57BL6 mice, the epitope-C5a a

61 labeled hemocyanin from Megathura crenulata (KLH) were prepared as effective immunoconjugates contain

62 ion compared with the group that was not fed KLH (P < 0.002).

63 Feeding KLH is followed by transient up-regulation of NOS2 mRNA

64 Feeding KLH to the C57BL/6J NOS2(-/-) mice elicited heightened T

65 e are still effectively inhibited by feeding KLH.

66 robust in C57BL/6J NOS2(-/-) mice following KLH/CFA immunization, including the magnitude of the del

67 Blood for KLH-induced T-cell proliferation and serum for anti-KLH

68 esponse was detected in 7 of 10 patients for KLH and 3 of 6 patients for tumor lysates.

69 oma, because it bypasses the requirement for KLH conjugation and adjuvant administration.

70 ssion of alpha4beta7 on T cells specific for KLH or tetanus toxoid was studied.

71 e adduction reactions were inhibited by free KLH and by reduction of glycated peptides with borohydri

72 Furthermore, KLH-g inhibited binding of GXM by serum of mice immunize

73 ed that of QS-21 in evaluations with the GD3-KLH melanoma conjugate vaccine.

74 unized mice were still capable of generating KLH-specific gamma interferon (IFN-gamma) as well as cor

75 nhibited by KLH treated with glutaraldehyde (KLH-g), but not by P315.

76 These glycopeptide/KLH conjugates were then used for antibody generation.

77 GM2-KLH/QS-21 (GMK) is a chemically defined vaccine that is

78 GM2-KLH/QS-21 vaccination does not improve outcome for patie

79 it was concluded that both GM2-MPLA and GM2-KLH are promising candidates as therapeutic cancer vacci

80 RTC 18961 trial compared the efficacy of GM2-KLH/QS-21 vaccination versus observation.

81 The GM2-KLH/QS-21 vaccine induces high immunoglobulin M (IgM) an

82 ncer stage II) were randomly assigned to GM2-KLH/QS-21 vaccination (n = 657) or observation (n = 657)

83 It was suggested that GM3PhAc-KLH is a promising vaccine candidate for glycoengineered

84 assess the surmountability potential of GNC-KLH-induced antibody titers by cocaine self-administrati

85 ed with controls, animals immunized with GNC-KLH did not reinstate cocaine self-administration behavi

86 Active immunization with GNC-KLH produced approximately an 8-fold rightward shift of

87 bjected to an immunization protocol with GND-KLH or treated with the mAb GNC92H2.

88 Active immunization with GND-KLH produced a 76% decrease in the ambulatory measure (c

89 GNE-KLH (keyhole limpet hemocyannin) was found to elicit per

90 Catalytic antibodies induced by GNT-KLH were also shown to produce potent titers and suppres

91 In the control group, KLH feeding (50 and 250 mg) before immunization and boos

92 ably, cancer patients immunized with globo H-KLH produce anti-globo H antibody levels often exceeding

93 m samples of patients immunized with globo H-KLH were compared.

94 ocyanin; KLH) and recall (Bet v 1) Ags (H4B4*KLH and H4B4*Bet v 1) induced significantly less CD4 cel

95 In H4B4*KLH-pulsed MoDC, the duration of KLH residence in MHC cl

96 acellular vesicles from supernatants of H4B4*KLH-pulsed MoDC contained significantly more HLA-DR and

97 Paradoxically, MoDC pulsed with H4B4*KLH, but not the other KLH preparations, induced robust

98 ein conjugated to keyhole limpet hemocyanin (KLH) (TCR Id:KLH) and injected with a chemical adjuvant

99 roduction of anti-keyhole limpet hemocyanin (KLH) Ab, increasing anti-KLH IgG, IgG2a, and IgE, wherea

100 eous boosts of Id/keyhole limpet hemocyanin (KLH) administered with adjuvant.

101 Id) conjugated to keyhole limpet hemocyanin (KLH) and administered with granulocyte-monocyte colony-s

102 alently linked to keyhole limpet hemocyanin (KLH) and monophosphoryl lipid A (MPLA) to form novel the

103 foreign proteins, keyhole limpet hemocyanin (KLH) and tetanus toxoid (TT), as well as an HLA A2.1-res

104 conjugates, Tn(c)-keyhole limpet hemocyanin (KLH) and Tn(c)-palmitic acid (PAM) with the saponin immu

105 23, conjugated to keyhole limpet hemocyanin (KLH) as a carrier and given with Bacillus Calmette-Gueri

106 tide (Flu-MP) and keyhole limpet hemocyanin (KLH) as control antigens.

107 Subjects were fed keyhole limpet hemocyanin (KLH) before subcutaneous immunization and booster immuni

108 thiolated MEP to keyhole limpet hemocyanin (KLH) by using succinimidyl-4-(N-maleimidomethyl)cyclohex

109 the glycoprotein keyhole limpet hemocyanin (KLH) can cross-link with reactive carbonyl residues on p

110 ycopeptide to the keyhole limpet hemocyanin (KLH) carrier protein completed the preparation of the va

111 aleimide-modified keyhole limpet hemocyanin (KLH) carrier protein through backbone Cys residues.

112 SF, or linkage to keyhole limpet hemocyanin (KLH) carrier protein were increasingly potent in their a

113 this problem, the keyhole limpet hemocyanin (KLH) conjugates of a series of GM3 derivatives were synt

114 human betaS, and keyhole limpet hemocyanin (KLH) control proteins induced no symptoms or pathology.

115 re immunized with keyhole limpet hemocyanin (KLH) first orally and then parenterally or only parenter

116 munogenic protein keyhole limpet hemocyanin (KLH) for 24 h and then combined.

117 and conjugated to keyhole limpet hemocyanin (KLH) for examining its immunogenicity.

118 OH) conjugated to keyhole limpet hemocyanin (KLH) has shown early proof-of-efficacy in rodents as a c

119 ine immunogen GNC-keyhole limpet hemocyanin (KLH) in preventing cocaine self-administration reinstate

120 peptide (MP) and keyhole limpet hemocyanin (KLH) in two healthy subjects.

121 nized with the Ag keyhole limpet hemocyanin (KLH) mixed with HKL generated a KLH-specific primary res

122 munoconjugate GND-keyhole limpet hemocyanin (KLH) or with the anti-cocaine mAb GNC92H2 were assessed

123 ically coupled to keyhole limpet hemocyanin (KLH) plus granulocyte macrophage colony-stimulating fact

124 munogenic protein keyhole limpet hemocyanin (KLH) protects mice from tumor challenge with the murine

125 leimide-activated keyhole limpet hemocyanin (KLH) provided a PI3P immunogen, which was successfully u

126 nsgenic mice with keyhole limpet hemocyanin (KLH) resulted in a decrease in anti-KLH IgG accompanied

127 ation including a keyhole limpet hemocyanin (KLH) study and a collagen-induced arthritis (CIA) diseas

128 ted efficacy in a Keyhole Limpet Hemocyanin (KLH) study in rats, where the blockade of PI3Kdelta acti

129 ently linked with keyhole limpet hemocyanin (KLH) to generate Id/KLH.

130 n carrier protein keyhole limpet hemocyanin (KLH) using glutaraldehyde has shown promising results in

131 Keyhole limpet hemocyanin (KLH) was beneficial in earlier studies.

132 GXM conjugated to keyhole limpet hemocyanin (KLH) with glutaraldehyde developed Abs to GXM.

133 hallenge with TNP-keyhole limpet hemocyanin (KLH), Ab production in these mice was hapten-, carrier-,

134 ovalbumin (OVA), keyhole limpet hemocyanin (KLH), and a bis-maleimide; KLH conjugates are also made

135 re immunized with keyhole limpet hemocyanin (KLH), and blood samples were taken.

136 n helper protein, keyhole limpet hemocyanin (KLH), can augment the efficacy of tumor lysate-pulsed de

137 dose of 20 mg of keyhole limpet hemocyanin (KLH), followed by s.c. immunization with KLH/CFA.

138 ed to the protein keyhole limpet hemocyanin (KLH), has been in clinical evaluation.

139 y DCs pulsed with keyhole limpet hemocyanin (KLH), HLA-A*0201-positive restricted influenza matrix pe

140 PC conjugated to keyhole limpet hemocyanin (KLH), T15 Id(+) Abs constitute >90% of the serum Ig in B

141 ion protocol (mAb-keyhole limpet hemocyanin (KLH)-Calmette-Guerin bacillus (BCG), an autologous anti-

142 HDK-1 T cells (a keyhole limpet hemocyanin (KLH)-specific CD4+ Th1 clone) in the presence of KLH, th

143 e (N-MoPn), and a keyhole limpet hemocyanin (KLH)-specific cell line (KLH-1).

144 econdary antigen, keyhole limpet hemocyanin (KLH).

145 n peptide or with keyhole limpet hemocyanin (KLH).

146 immunization with keyhole limpet hemocyanin (KLH).

147 immunization with keyhole limpet hemocyanin (KLH).

148 8 E7 antigens and keyhole limpet hemocyanin (KLH; an immunological tracer molecule) and delivered in

149 ization with Ars-keyhole limpet hemocyanin, (KLH) and at day 6, large clusters of Ars-specific B cell

150 gates of primary (keyhole limpet hemocyanin; KLH) and recall (Bet v 1) Ags (H4B4*KLH and H4B4*Bet v 1

151 against the hypusine-containing hexapeptide-KLH and hypusine-containing hexapeptide-bis-maleimide co

152 containing and lysine-containing hexapeptide-KLH conjugates.

153 in monomers of keyhole limpet hemocyanin (IC(KLH)) to create the MCV ICKLH-SOO9.

154 upport the evaluation of sulfhydryl-based Id-KLH vaccines in lymphoma clinical trials and possibly th

155 Importantly, standard glutaraldehyde Id-KLH conjugation procedures could result in "overconjugat

156 umor-bearing mice, whereas glutaraldehyde Id-KLH had little efficacy.

157 However, glutaraldehyde Id-KLH vaccines fail to elicit anti-Id immune and clinical

158 arrier protein keyhole limpet hemocyanin (Id-KLH).

159 with human Igs analogous to those used in Id-KLH clinical trials.

160 Maleimide Id-KLH conjugates eradicated A20 lymphoma from most tumor-b

161 Maleimide Id-KLH elicited tumor-specific IgG Abs and T cells, with CD

162 Maleimide Id-KLH vaccines also demonstrated superior efficacy in 38C1

163 accination received booster injections of Id-KLH protein, and tumor regression was observed in 3 of t

164 istry was used to enhance the efficacy of Id-KLH vaccines.

165 Subsequent boosting with Id-KLH can lead to tumor regression despite apparent resist

166 e immunity superior to that obtained with Id-KLH plus a chemical adjuvant, and protection was not dep

167 Vaccination with Id-KLH-pulsed DCs induced tumor-protective immunity superio

168 The administration of Id-pulsed DC and Id/KLH vaccines were well tolerated with patients experienc

169 yhole limpet hemocyanin (KLH) to generate Id/KLH.

170 Further study of Id/KLH is recommended in other settings where efficacy may

171 tients received at least one injection of Id/KLH, and 31 were assessed for efficacy.

172 Patients received Id/KLH 1 mg on day 1 subcutaneously, with granulocyte-macro

173 This trial demonstrates that Id/KLH alone can induce tumor regression and durable object

174 rapy of T cell lymphoma compared with TCR Id:KLH with QS-21 vaccines.

175 d to keyhole limpet hemocyanin (KLH) (TCR Id:KLH) and injected with a chemical adjuvant (QS-21) induc

176 tive Ag or Ag conjugated to control mAb (ISO*KLH and ISO*Bet v 1).

177 limpet hemocyanin (KLH)-specific cell line (KLH-1).

178 demonstrated the ability of the tumor lysate/KLH-pulsed DC to generate specific T-cell responses and

179 In addition, m1E41920-KLH elicited a specific IgG response to PI Ag, and immun

180 onse to PI Ag, and immune sera from m1E41920-KLH-immunized mice was able to inhibit C. burnetii infec

181 Furthermore, m1E41920-KLH was able to confer significant protection against C.

182 Thus, m1E41920-KLH is a protective Ag and may be useful for developing

183 Sera from patients administered mAb-KLH+BCG followed by AAAP contained three distinct classe

184 0-kDa IL-6 complexes, while 2) sera from mAb-KLH+BCG patients contained 200-kDa IL-6 complexes inacti

185 Maleimide KLH conjugation was easily performed with human Igs anal

186 impet hemocyanin (KLH), and a bis-maleimide; KLH conjugates are also made with the deoxyhypusine- and

187 c activity was lower only in the sera of MEP-KLH conjugate-immunized mice with preexisting antibodies

188 contrast to the native MEP polymer, the MEP-KLH conjugate vaccine induced high titers of MEP-specifi

189 cited by follow-up immunization with the MEP-KLH conjugate.

190 Vaccination with MEP-KLH conjugate induced opsonic antibodies broadly cross-r

191 Sera from mice immunized with MEP-KLH conjugate, but not from animals immunized with compa

192 Immunization with MEP-KLH elicited a significant proportion of antibodies spec

193 Tn(c), when given with the carrier molecule KLH and QS21, stimulated the production of high-titer im

194 Sera from mice immunized with either native KLH or KLH-g cross-reacted with several other carbohydra

195 ne of beta2-adrenergic receptor (beta2AR)neg KLH-specific Th2 cells and resting trinitrophenyl (TNP)-

196 Responses to neoantigen (KLH) and T cell-independent responses to pneumococcal va

197 ly reduced the recruitment of P-MoPn but not KLH-1 to the genital tract.

198 ease indistinguishable from control mice not KLH primed.

199 in response to T dependent Ags, SRBC, and NP-KLH.

200 ophenyl acetyl-keyhole limpet hemocyanin (NP-KLH) and NP-OVA develops within ectopic lymphoid tissue

201 NP)-conjugated keyhole limpet hemocyanin (NP-KLH) or ovalbumin(323-337) peptide, using either U1 RNA

202 before immunization with NP-KLH alone or NP-KLH mixed with alpha-GC.

203 with wt, sheep red blood cell (SRBC)-, or NP-KLH-immunized SWAP-70(-/-) mice have strongly reduced nu

204 vivo for normal Th2 humoral responses to NP-KLH (4-hydroxy-3-nitrophenylacetyl/keyhole lymphocyte he

205 CD1d(-/-) donors before immunization with NP-KLH alone or NP-KLH mixed with alpha-GC.

206 djuvant, alum, U1 RNA coadministered with NP-KLH enhanced production of NP-specific IgM and IgG (on d

207 was greatly enhanced by immunization with NP-KLH.

208 Moreover, administration of KLH with HKL as an adjuvant reversed established immune

209 Analysis of KLH-specific antibody responses, KLH-specific cytokines,

210 In H4B4*KLH-pulsed MoDC, the duration of KLH residence in MHC class II loading compartments was s

211 needed to clarify the immunologic effects of KLH and the effects of KLH on progression.

212 mmunologic effects of KLH and the effects of KLH on progression.

213 In this study, safety and efficacy of KLH were compared with that of mitomycin (MM).

214 tio even following a booster immunization of KLH/CFA.

215 oduction of Th2 cytokines and high levels of KLH-specific IgE and induced a Th1-type response with hi

216 -specific CD4+ Th1 clone) in the presence of KLH, they showed conspicuous cell death as measured by p

217 ltured with HDK-1 T cells in the presence of KLH.

218 ion of Th1 cytokines and large quantities of KLH-specific IgG2a Ab.

219 indicating that glutaraldehyde treatment of KLH reveals an epitope(s) that cross-reacts with GXM.

220 ardization issues associated with the use of KLH and BCG in the clinical setting have prompted us to

221 ns, suggesting the cross-reactive epitope on KLH was not protective.

222 A beta(1-42) or KLH vaccinations were started in these animals at 12 mon

223 intact when incubated with either T cells or KLH alone.

224 rom mice immunized with either native KLH or KLH-g cross-reacted with several other carbohydrate Ags,

225 MoDC pulsed with H4B4*KLH, but not the other KLH preparations, induced robust proliferation of CD4 ce

226 XM-binding Abs from mice immunized with P315-KLH were inhibited by KLH treated with glutaraldehyde (K

227 e immunological response in cancer patients, KLH is also an immunogenic carrier protein to elicit T-c

228 ls in the spleen in a primary response to PC-KLH.

229 hydrate vaccine 1 and to the carrier protein KLH to form semisynthetic vaccine 2.

230 and Tn-to maleimide-modified carrier protein KLH.

231 immunization and booster resulted in reduced KLH-specific T-cell proliferation compared with the grou

232 Analysis of KLH-specific antibody responses, KLH-specific cytokines, and local inflammation demonstra

233 Specific KLH antibody response was significantly decreased in juv

234 nce and accuracy when tested on the standard KLH dataset.

235 Eleven of the 12 patients generated strong KLH-specific cellular proliferative immune responses sho

236 and Ab in protective immunity induced by TCR-KLH immunization.

237 iated component of protection induced by TCR-KLH vaccines.

238 These results suggest that TCR-KLH vaccine-induced tumor protection in the C6VL system

239 ecific Ak-restricted B10.BR TCL and by a Th1 KLH-specific, Ek-restricted B10.BR T cell clone.

240 ollectively, these findings demonstrate that KLH addition to tumor antigen-pulsed DC immunizations ca

241 In addition, the KLH-specific IL-4 was suppressed in infected mice immuni

242 Both clones and the KLH-1 line expressed similar levels of the adhesion mole

243 No difference in the KLH-induced proliferation was found between the total an

244 Also, clones P-MoPn and N-MoPn but not the KLH-1 line migrated to the mesenteric lymph node, sugges

245 tion removed a significant proportion of the KLH-specific cells (mean decrease in proliferative respo

246 elicited low levels of immune response, the KLH conjugates of N-propionyl, N-butanoyl, N-iso-butanoy

247 nd in significantly greater numbers than the KLH-specific T-cell line.

248 2) TNP-KLH-immunized IL-2-/- mice administered anti-CD3 and coa

249 3) TNP-KLH-immunized IL-2+/+ mice administered anti-TGF-beta mA

250 ir ability to induce Th2 responses after TNP-KLH challenge and that such immunization also leads to a

251 In addition, thymocytes from TNP-KLH-immunized IL-2 -/- mice produce more IFN-gamma and l

252 1) LP T cells from TNP-KLH-immunized IL-2-/- mice administered anti-CD3 (i.p.)

253 rinitrophenyl-keyhole limpet hemocyanin (TNP-KLH).

254 eta early (day 2), whereas LP T cells in TNP-KLH-immunized IL-2+/+ mice exhibit an approximately eigh

255 We show that LP T cells in TNP-KLH-immunized IL-2-/- mice fail to produce TGF-beta earl

256 Even in the presence of overt infection, TNP-KLH-plus-rmIL-12-immunized mice were still capable of ge

257 ty of rmIL-12 to drive a Th1 response to TNP-KLH in the presence of an ongoing Th2-mediated disease.

258 and co-administration of anti-IL-12 with TNP-KLH completely prevented colitis and significantly reduc

259 shed, groups of mice were immunized with TNP-KLH in the presence or absence of exogenous rmIL-12.

260 Moreover, rmIL-12 administered with TNP-KLH late in infection did not alter the parasite-specifi

261 ugate the sTn double C-glycoside hapten 2 to KLH carrier protein for biological evaluation as a vacci

262 % of patients treated with MTX alone) and to KLH vaccine (47% of patients had detectable anti-KLH IgG

263 Serum antibody to KLH was present only after immunization in the control g

264 ermitting the conjugation of the antigens to KLH via reductive amination.

265 Priming of CD4(+) T cells to KLH was observed in all 9 subjects injected with KLH-pul

266 Priming of T cells to KLH was seen in 6 of 10 patients and to tumor in 3 of 7

267 control peptides P315 and P24 conjugated to KLH also elicited Abs to GXM.

268 dult zebra finches against VIP conjugated to KLH and compared neuronal recruitment in their brains, w

269 to that induced by mAb MK2-23 conjugated to KLH and given with Freund's adjuvant.

270 e Ags, many of which have been conjugated to KLH for vaccine development.

271 hydrocodone-based haptens were conjugated to KLH to generate immunogens that would recognize both oxy

272 ping HTT Exon1 coded peptides, conjugated to KLH, delivered with alum adjuvant.

273 results indicate that conjugation of MEP to KLH significantly enhances its immunogenicity and the el

274 e showed strong proliferation in response to KLH in vitro.

275 of IFN-gamma, IL-4, and IL-10 in response to KLH.

276 also controlled Tfh memory cell responses to KLH stimulation more efficiently than CD80/86 blockade.

277 bited T cell-dependent antibody responses to KLH without significant peripheral B cell depletion.

278 nted total IgG, IgG1, and IgG2a responses to KLH/CFA compared with that seen in Ag-fed wild-type mice

279 Vaccination with KLH-g or unmodified KLH elicited Abs to GXM, but did not confer protection a

280 dition to describing the complexity of using KLH and glutaraldehyde in the development of vaccines to

281 f interferon-gamma (IFN-gamma) and IL-4 when KLH-pulsed B cells or spleen cells were used as antigen

282 While KLH-GM3 elicited low levels of immune response, the KLH

283 atants from (i) CD4(+) T cells cultured with KLH-pulsed DC or (ii) DC cultured with recombinant GM-CS

284 In contrast, maternal immunization with KLH, a T cell-dependent nonmammalian antigen, did not in

285 ponses, respectively, than immunization with KLH-conjugated mAb MK2-23 and separate administration of

286 We found that after immunization with KLH-DNP, mice deficient for both CD28 and HSA lack DNP-s

287 gG and IgM formation after immunization with KLH.

288 in (KLH), followed by s.c. immunization with KLH/CFA.

289 lymph nodes draining the skin immunized with KLH and their production of IFN-gamma, IL-4, and IL-10 i

290 T cells from GM-CSF -/- mice immunized with KLH showed impaired proliferative responses and produced

291 ns in volunteers parenterally immunized with KLH, regardless of whether a preceding mucosal priming h

292 tor (GM-CSF) to a control immunotherapy with KLH plus GM-CSF.

293 was observed in all 9 subjects injected with KLH-pulsed DCs, and boosting of TT-specific T-cell immun

294 16 adjuvant intravesical instillations with KLH after preimmunization, and 270 patients were randoml

295 DCs pulsed with KLH and mouse tyrosinase-related protein-2 peptide resul

296 ed streptozotocin-induced diabetic rats with KLH to assess the capacity of the elicited antibodies to

297 nprotective mAb, cross-reacted strongly with KLH-g.

298 Vaccination with KLH-g or unmodified KLH elicited Abs to GXM, but did not

299 n complete Freund's adjuvant with or without KLH.

300 ved after immunization with individual Le(y)-KLH vaccine constructs.